Home » Newsletters » BioWorld

BioWorld

Oct. 31, 1994

View Archived Issues

HOUSTON BIOTECH'S STOCK SOARS ON IMMUNOTOXIN RESULTS

BEAUFORT-IPSEN BUYS UK BIOTECH PIONEER PORTON INTERNATIONAL

SDI-1 FROM AGING CELLS JOINS P53 AS POTENTIAL PROLIFERATION CURB

OTHER NEWS TO NOTE

DAVID BLECH UNDER FIRE FROM FORMER BROKERS

LONDON STOCK EXCHANGE LOWERS BARRIERS TO LIST COMPANIES

IDEC REPORTS TUMOR SHRINKAGE IN PHASE II CLINICAL TRIAL RESULTS

NIH DEMANDS PIECE OF BRCA1 PATENT PIE

EXPERTS, LAWYERS PONDER NEW FDA RULES

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...